SMS Pharmaceuticals Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0nvhh0ud37ilscpcbju8ornr.pdf

Key Takeaways


Ibuprofen: The Growth Bet

Vamsi Krishna: "Definitely, I think ibuprofen quarter over quarter, again, as we discussed in the last conference call, we are adding more customers in every quarter. We are adding more geographic segments as well."

Margin Walk & Recovery Plan

Vamsi Krishna: "No, we will go back to the 20 plus percentage as it was previously there. So, EBITDA margins will definitely improve going forward."

Capex: Backward Integration First


Product & Therapeutic Mix


Competitive & Pricing Dynamics

Vamsi Krishna: "It has stabilized now, actually. I mean, it has normalized in the downside, but we are able to compete. We are able to get good market share, even at those prices."

Guidance & Commitments

CommitmentSpecificsTimeline
Top-line growth20%–25% revenue growth (conservatively ~25%)FY25
EBITDA marginRecover to 20% plus (~400 bps improvement from FY24's 16.4%)FY25
Ibuprofen revenue shareReach 25%–28% of total revenueFY25
Ibuprofen capacity utilizationHit 65%–70% (conservatively 65%)FY25
Capex deployment~INR150 crores, 50%–60% toward backward integrationDeployed over 8–9 months in FY25
Capex revenue contributionNew capex starts contributing to revenueFY26
Medium-term revenue targetReach INR1,200–INR1,300 croresNext 3–4 years
Medium-term EBITDA margin~20%, dependent on product mixNext 3–4 years

Key Metrics

MetricQ4 FY24
Revenue₹246 cr, +65% YoY
Full-year revenue₹709 cr, +36% YoY from ₹522 cr in FY23
EBITDA margin16.4% for FY24, +601 bps YoY
PAT₹17 cr, +178% YoY
Full-year PAT₹50 cr, turnaround from loss of ₹7 cr in FY23
Gross margin26%, down from ~32% in prior quarters due to raw material and solvent price increases
Dividend₹0.4 per share, 40% of face value, highest ever announced
API segment revenue₹242.1 cr, 98.5% of consolidated revenue
API export share89% of API revenue, including deemed exports
Anti-diabetic share29% of total sales
Ibuprofen share~19% of FY24 revenue
ARV share16% of total sales in Q4, ~20% for full year
Capacity utilization~65% overall
Ibuprofen capacity utilization~40% in Q4, full-year average ~25%
FY25 revenue growth guidance20% to 25%
FY25 EBITDA margin target~20%
FY25 capex plan~₹150 cr, funded via internal accruals, term loans, and ₹114.3 cr equity warrants
3–4 year revenue target₹1,200–₹1,300 cr
Ibuprofen FY25 revenue share target25% to 28% of total revenue
Ibuprofen FY25 capacity utilization target65% to 70%, conservatively 65%
R&D allocation40% cost optimization and backward integration, 60% new and niche products
VKT Pharma investment36.5% stake, ₹45 cr; VKT top line ~₹96 cr